Previous Close | 6.36 |
Open | 6.30 |
Bid | 0.00 x 1000 |
Ask | 0.00 x 1800 |
Day's Range | 6.07 - 6.45 |
52 Week Range | 2.07 - 9.30 |
Volume | |
Avg. Volume | 277,177 |
Market Cap | 131.791M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.16 |
Earnings Date | Mar 28, 2022 - Apr 01, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 27.33 |
If you want to know who really controls F-star Therapeutics, Inc. ( NASDAQ:FSTX ), then you'll have to look at the...
Proposed ~US$161 million all-cash acquisition to accelerate invoX’s strategy to build Sino Biopharm’s International Biopharmaceutical R&D Platform outside of China, transforming the lives of patients worldwideThe transaction demonstrates the strength of F-star’s differentiated bispecific antibody technology and provides backing from a top 40 global pharmaceutical company to accelerate growth and unlock potentialF-star’s unique next-generation tetravalent (2+2) bispecific antibody platform comple
F-star Therapeutics, Inc. ( NASDAQ:FSTX ) just released its latest quarterly results and things are looking bullish...